Vernalis PLC: Announcement of Results for Year Ended 31 Dec 2013

Vernalis PLC: Announcement of Results for Year Ended 31 Dec 2013 
WINNERSH, UNITED KINGDOM -- (Marketwired) -- 04/01/14 --  
1 April 2014 
LSE: VER 
Announcement of Results for the year ended 31 December 2013 
Vernalis plc (LSE: VER) today announces its audited results for the
year ended 31 December 2013. 
Financial Highlights 


 
--  Financial performance ahead of market expectations
    
    
--  Revenue was GBP14.1 million (2012: GBP14.6 million)

  
-Frovatriptan royalty income was up 16 % at GBP6.7 million (2012: 
GBP5.7 million) primarily due to a 14% increase in volume of
activepharmaceutical ingredient (API) supplied, with underlying
in-market sales made by Menarini flat 
- Research collaboration income was GBP7.1 million (2012: GBP8.7
million) including GBP2.5 million of milestones payments (2012:
GBP2.6 million) allowing our research organisation to remain
self-funding 


 
--  Operating costs before exceptional items were GBP19.3 million (2012:
    GBP18.2 million), up 6% due to preparatory activities for expansion
    into the US and investment in the NCE pipeline (V158866 and V81444)
    
    
--  Pre-exceptional loss for the year was GBP5.6 million (2012: GBP5.2
    million) and GBP4.0 million (2012: GBP5.2 million) on a
    
    post-exceptional basis
    
    
--  Cash resources including cash and cash equivalents and held to
    maturity assets reduced by GBP4.7 million in the year following:

  
-GBP2.0 million proof-of-concept milestone payment to Tris for CCP-01
and 
- GBP0.9 million foreign exchange loss on the conversion of cash held
in US dollars into sterling 


 
--  Balance sheet remains strong with GBP76.9 million of cash resources
    and no debt

  
Operational Highlights 
Cough Cold Commercial Pipeline: 


 
--  CCP-01 proof-of-concept achieved and milestone paid to Tris (March
    2013)
    
    
--  Successfully completed single and multi-dose pivotal bioavailability
    studies (November 2013 and February 2014), completing
     the clinical
    studies required for NDA filing
    
    
--  Positive interim six months stability data for CCP-01 has been
    generated and NDA filing on track for mid-2014
    
    
--  Four further programmes in active development at Tris, and we aim to
    achieve POC on all four of the remaining programmes during 2014

  
Frovatriptan (marketed) (Migraine): 


 
--  Underlying Menarini sales flat at EUR26.4 million (2012: EUR26.5
    million)
    
    
--  Menarini outlook for 2014 is for flat underlying sales vs 2013, both
    in tablet volumes and sales revenue
    
    
--  We expect Menarini to reduce stock in 2014 with 2 shipments of API,
    one in each half of the year

  
NCE Development Pipeline: 
V81444 (CNS diseases) 


 
--  Phase Ib/II POC study initiated (July 2013) with data anticipated in
    H1 2014

  
V158866 (Pain) 


 
--  Phase II POC study initiated (April 2013) and progressing well. Of a
    total of 36 subjects, 16 have completed and a further 4 are enrolled.
    Data now anticipated around the end of 2014

  
AUY922 (Cancer) 


 
--  Phase I and Phase II studies in multiple oncology indications
    including lung and breast continue with Novartis

  
Tosedostat - CHR2797 (Cancer) 


 
--  Cell Therapeutics reported positive interim results from an
    investigator-initiated Phase II trial at the 55th American Society of
    Haematology annual meeting (December 2013)
    
    
--  The partial clinical hold on investigator led trials was removed by
    FDA in January 2014 enabling studies to resume

  
RPL554 


 
--  Anti-inflammatory study results announced by Verona Pharma (March
    2013)
    
    
--  Verona announced a successful GBP14 million fundraising in March 2014.
    Some of the proceeds are intended to be used to develop RPL554 in
    three clinical studies using a nebulised formulation in patients with
    severe COPD and additional studies are planned to prepare for a larger
    Phase IIb study in hospitalised COPD patients. Results are expected
    in
    2015

  
Research Collaborations: 


 
--  New collaboration with AKP announced (October 2013) and GBP0.3 million
    milestone earned (March 2014)
    
    
--  First Servier collaboration extended for a further 2 years (March
    2013)
    
    
--  GBP2.5 million of milestones earned from successful collaboration with
    Genentech (February and March 2013)

  
Expected 2014 Newsflow: 


 
--  V81444 (CNS diseases) - Complete Phase Ib/II POC study (Data H1 2014)
    
    
--  CCP-01 - Filing of NDA (Mid 2014)
    
    
--  Proofs-of-concept on all four remaining programmes in cough cold
    pipeline (by 2014 year end)
    
    
--  V158866 (Pain) - Complete Phase II POC study (Data around 2014 year
    end)
    
    
--  AUY922 (Cancer) - Multiple Phase I and II study results (Novartis)
    (undisclosed)
    
    
--  Tosedostat - CHR2797 (Cancer)- Phase II study results (Chroma)
    (undisclosed)
    
    
--  Achieve milestones under existing collaborations (undisclosed)
    
    
--  Secure new research collaborations (undisclosed)

  
Ian Garland, Chief Executive Officer, commented, "We made significant
progress across all three elements of our strategy during 2013 and
continued our strong financial and operational performance. Our lead
cough cold programme, CCP-01, progressed rapidly achieving
proof-of-concept, successfully completing both required pivotal
clinical studies and achieving six month accelerated stability. We
are on target therefore for an NDA filing in mid-2014. With four
further cough cold programmes in development we aim to achieve POC on
all four of these programmes in the coming year.  
In the NCE pipeline we initiated two POC studies for V81444 and
V158866 and expect data from both, during 2014. We also had another
positive year in our research business following on from last year's
record performance and continue to be self-funding.  
The outlook for 2014 and beyond is extremely positive as we get
closer to our first NDA filing from the cough cold portfolio and its
potential approval in the first half of 2015." 
Presentation & Conference Call 
Vernalis management will host a presentation at 9.00am (UK) at 
Brunswick's offices, 16 Lincoln's Inn Fields, London WC2A 3ED today.
It
 will also be available via webcast at http://www.vernalis.com/ 
investor-centre/presentations-and-webcasts and www.cantos.com and
via
 conference call, which can be joined by dialling: +44 (0) 20 3139
4830,
 Passcode #35707904. 
Enquiries: 
Vernalis plc:
 Ian Garland, Chief Executive Officer 
 +44 (0) 118 938
0015
 David Mackney, Chief Financial Officer 
Canaccord Genuity Limited (Nominated Adviser): 
 +44 (0) 20 7523
8350
 Lucy Tilley
 Dr Julian Feneley
 Henry Fitzgerald-O'Connor 
Shore Capital (Joint Broker) 
 +44 (0)20 7408 4090
 Bidhi Bhoma
 Toby
Gibbs 
Brunswick Group: 
 +44 (0) 20 7404 5959
 Jon Coles 
Click on, or paste the following link into your web browser, to view 
the associated PDF document. 
http://www.rns-pdf.londonstockexchange.com/rns/6618D_1-2014-3-31.pdf 
This information is provided by RNS
 The company news service from
the London Stock Exchange 
END  
Contacts:
RNS
Customer
Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com
 
 
Press spacebar to pause and continue. Press esc to stop.